AstraZeneca expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes medicine. CEO Pascal Soriot spoke to Anna Edwards, Guy Johnson and Tom Mackenzie on Bloomberg's The Opening Trade about the company's earnings, outlook, and its pipeline of new medicines. This interview occurred Tuesday, February 10.